##
|Contents|||
|---|---|---|
|Reference and administrative|information|3|
|Report ofthe Trustees||4-22|
|Statement of Responsibilities|ofthe Trustees|23|
|Independent
auditor's
report|to the members ofWorld Cancer Research Fund|24-26|
|Statement offinancial
activities||27|
|Balance sheet||28|
|Statement ofcash flows||29|
|Notes to the financial
statements||30-43|
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
|j~iVf'easncremecnt|.. z,„.
,:,
.„+.
':+**.**$~AinpunVs'~~+ Q"~+~-'~":;;+'~-|.. z,„.
,:,
.„+.
':+**.**$~AinpunVs'~~+ Q"~+~-'~":;;+'~-|
|---|---|---|
|Open rate||38.4%|
|Click throughs'||2.6%|
|Clicks per unique open'||7.4%|
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
||||||Unrestricted|Restricted|||
|---|---|---|---|---|---|---|---|---|
||||||funds|funds|Total funds|Total funds|
||||||2022|2022|2022|2021|
||||||Total|Total|Total|Total|
|Income and endowments||from:|||||||
|Donations,
legacies,|||||||||
|grants and other income|||||10,614,545|185,072|10,799,617|10,811,446|
|Investment
income|||||18,231||18,231|1,779|
|||Total income|||10,632,776|185,072|10,817,848|10,813,225|
|Expenditure
on:|||||||||
|Raising funds|||||2,522,442||2,522,442|2,480,044|
|Charitable
activities|||||8,355,867|77,007|8,432,874|8,275,088|
||Total expenditure||||10,878,309|77,007|10,955,316|10,755,132|
|Net losses on investments|||||||||
|Currency
gain/(loss)|||||9,850||9,850|(744),|
|(Expenditure)/income|||||(235,683)|108,065|(127,618)|57,349|
|Fund balances
brought|forward||at||6,454,849|59,374|6,514,223|6,456,874|
|I October 2021|||||||||
|Fund balances carried forward at||||21|6,219,166|167,439|6,386,605|6,514,223|
|30September 2022|||||||||
|Balance sheet|Balance sheet||||||
|---|---|---|---|---|---|---|
|at30September|ZOZZ||||||
||||||2022|2021|
|Fixed assets:|||||||
|Tangible assets||||10|424,730|493,471|
|Investments||||11|||
|||Total fixed assets|||424,730|493,471|
|Current assets:|||||||
|Debtors||||12|1,065,111|2,159,087|
|Cash at bank and|in|hand
I|||10,216,774|7,996,390|
|||Total current assets|||11,28],885|10,155,477|
|Liabilities:|||||||
|Creditors: amounts||falling due within one year||13|(2,591,244)|(1,760,494)|
|||Net current assets|||8,690,641|8,394,983|
|||Total assets less current|liabilities||9,115,371|8,888,454|
|Creditors:
amounts||falling due after one year||14|(2,728,766)|(2,374,231)|
|Total net assets|at|30September|||6,386,605|6,514,223|
|The funds ofthe|charity:||||||
|Unrestricted
funds|||||6,219,166|6,454,849|
|Restricted funds|||||167,439|59,374|
|Total funds|||||6,386,605|6,514,223|
|||||||2022|2021|
|---|---|---|---|---|---|---|---|
|Cash flows from operating
activities:||||||||
|Net cash provided
by operating
activities||||||2435,146|1,305,010|
|Cash flows from investing
activities:||||||||
|Dividends
and interest
from investments||||||18,231|1,779|
|Proceeds from sale ofequipment||||||400||
|Purchase ofequipment||||||(33,393)|(45,081)|
|Net cash provided
by (used in) investing||activities||||(14,762)|(43,302)|
|Change
in cash and cash equivalents|in|the|reporting|period||2,220,384|1,261,708|
|Cash and cash equivalents
at the beginning|||ofthe reporting||period|7,996,390|6,734,682|
|Cash and cash equivalents
at the end|of|the|reporting|period||10,216,774|7,996,390|
|Reconciliation
ofnet expenditure
to|net|cash flow||||||
|from operating
activities||||||||
|Net expenditure
for the reporting
period||||||(127,618)|57,349|
|Depreciation
charges||||||101,509|92,360|
|Dividends
and interest
from investments||||||(18,231)|(1,779)|
|Loss on sale offimd assets||||||225||
|Decrease/(increase)
in debtors||||||1,093,976|(250,396)|
|Increase
in creditors||||||1,185,285|1,407,476|
|Net cash provided
by operating
activities||||||2,235,146|1,305,010|
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
|||Unrestricted|Restricted|2022|2021|
|---|---|---|---|---|---|
|||Funds|Funds|Total|Total|
|||||f||
|Donations||5+61,257|185,072|5,446,329|5,983,490|
|Legacy income||2,312,783||2+12,783|1,995,406|
|Committed|giving|1,293,807||1493,807|1,265,208|
|Gift Aid||877,422||877,422|858,279|
|Grants from|affiliates|674,924||674,924|689,751|
|Grant revenue||182,577||1S2,577|18,563|
|Other income||11,775||11,775|749|
|||10,614,545|185,072|10,799,617|10,811,446|
|4|Expenditure|Expenditure|on raising funds|||||
|---|---|---|---|---|---|---|---|
|||||Direct|Support|2022|2021|
|||||costs|costs|Total|Total|
|Fundraising||actvit ies||162,738||162,738|179,476|
|Direct mail||fundraising||1,566,280||1,566,280|1,636,613|
|Human|resources||||557,589|557,589|46,278|
|Premises|||||129,385|129,385|I II,0I8|
|Other|||||106,450|106,450|88,659|
|||||1,729,018|793,424|2,522,442|2,062,044|
##
|Expenditure|Expenditure|on charitable|activities||||
|---|---|---|---|---|---|---|
||||Direct|Support|2022|2021|
||||costs|costs|Total|Total|
|Research:|||||||
|Research grants*|||1,977,475||1,977,475|2,639,610|
|Other direct|costs||126,978||126,978|165,638|
|Human
resources||||859,616|859,616|867,997|
|Premises||||199,469|199,469|207,555|
|Other||||770,605|770,605|163,984|
||||2,104,453|1,829,690|3,934,143|4,044,784|
|Information|&education:||||||
|Programme|grants to affiliates||442,540||442,540|373,713|
|Publications|||2,022,395||2,022,395|2,058,413|
|Consulting|fees||402,161||402,161|41],690|
|Other direct|costs||345,933||345,933|406,308|
|Human
resources||||911)463|911,463|723,265|
|Premises||||210,251|210,251|164,113|
|Other||||163,988|163,988|92,802|
||||3,213,029|1,285,702|4,498,731|4,230,304|
|Total costs|ofcharitable|activities|5,317,482|3,115,392|8,432,874|8,275,088|
|'includes
grant refunds|||||||
##
##
|Murdoch|Childrens|Childrens|Childrens|Research|Body mass index in childhood
and risk of|pre-menopausal|pre-menopausal|pre-menopausal|349,800|
|---|---|---|---|---|---|---|---|---|---|
|Institute|||||breat cancer|||||
|Northumbria||University|||The role ofmaternal
folate in childhood
leukemia|||initiation;|346&625|
||||||understanding
the molecular
mechanisms|||||
|Queens University||||ofBelfast|Periprostatic
adipose tissue and advanced|prostate cancer|||346,394|
||||||risk; aprospective
study|||||
|Italian National|||Council ofResearch||Integrating
tissue, based spatial information|to elucidate how|||340,000|
||||||obesity-induced
tumour
metabolites
dirve|prostate cancer||||
||||||progres sion|||||
|University||ofAberdeen|||The feasbility
and acceptability
ofconducting||a randomised||59,994|
||||||controller
trial to improve
body composition||of|||
||||||gastrointestional
cancer survivors
in India|||||
|IDISBA|||||Dietary
and lifestyle
patterns
and the risk|ofbreast cancer|||15,000|
|IDISBA|||||Updating
systematic
literature
review
on|diet|and|lifesty le|11,787|
||||||patterns
and breast cancer|||||
|IUNS|||||IUNS taskforce on nutrition
and cancer||||14,329|
|UICC|||||Partnership
for Advocacy
Support||||37,278|
|IARC/WHO|||||Consortium
Agreement
for the Cancer Prevention|||Europe|13,077|
||||||Project|||||
|NHS NIHR|||||NIHR Cancer and Nutrition
Collaboration||||74,500|
||||||Total research
grants||||1,608,784|
|Imp erial|College||||Continuous
review||||372,880|
||||||Grant Refunds||||(4,189)|
||||||Total grants||||1,977,475|
##
|Notes|to the fin|ancial|statem|ents
(confinued)||||
|---|---|---|---|---|---|---|---|
|6|Grants and|grants|payable|(continued)||||
|||||||2022|2021|
|Beginning grants pay||able||||3,591,512|2,122,309|
|New|grant funding|||||1,442,813|2,312,485|
|Grant|adjustment|||||40,869|744|
|Grant|payments|||||(986,212)|(844,026)|
|Ending grants payable||||||4,088,982|3,591,512|
|Due within one year||(note 13)||||1,360+16|1,217,281|
|Due after one year (note 14)||||||2,728,766|2,374,231|
|7|Supportcosts|||||||
|||||||2022|2021|
|||Fundraising||Information|Research||f|
|||||& education||||
|Human|resources||557,589|911,463|859,616|2,328,668|2,055,540|
|Premises|||129,385|210,251|199,469|539,105|482,686|
|Other|||106,450|163,989|770,605|1,041,044|345,446|
||||793,424|1,285,703|1,829,690|3,908,817|2,883,672|
|Notes to the|Notes to the|financial|statements|statements|(continued)|||
|---|---|---|---|---|---|---|---|
|8|Operating
costs|||||||
|||||||2022|2021|
||||||||E|
|Net expenditure||is stated after charging:||||||
|Depreciation
and||other amounts|written offtangible fixed assets:|||||
|Owned||||||101,509|92,360|
|Hire ofp|lant and|machinery||||14,779|15,248|
|Hire ofother assets - operating|||leases|||313,000|313,000|
|||||||2022|2021|
|Auditor's|remuneration:|||||||
|Audit of|these financial statements|||||27,500|25,000|
|Audit of|financial|statements
ofsubsidiaries||||3,000|2,000|
|||||||30,500|27,000|
|9|Human|resources||||||
|||||||2022|2021|
|Salaries||||||1,895,608|1,683,018|
|Social security
costs||||||216,960|179,550|
|Pension|costs- defined contribution|||scheme||86,860|74,844|
|Employee benefits||||||48,076|54,676|
|Recruitment||||||63,110|26,510|
|||||||2,310,614|2,018,598|
|The average number ofpersons employed
during
the y|ear, analysed
by category, was as follows:||
|---|---|---|
||2022|2021|
||Number|Number|
|Fundraising|12|13|
|Research|13|10|
|Education|13|l2|
|Administration|10|10|
||48|45|
##
|10
Tangible|fixed assets|||||
|---|---|---|---|---|---|
|||Leasehold|Fixtures|Machinery|Total|
|||improvements|and|and||
||||fittings
f|equipment
f||
|Cost||||||
|At
I October 2021||482,449|64,676|167,060|714,185|
|Additions||||33,393|33,393|
|Disposals||||(1,249)|(1,249)|
|At 30 September 2022||482,449|64,676|199,204|746,329|
|Depreciation||||||
|At
1 October 2021||100,864|26,044|93,806|220,714|
|Charge for year||49,237|12,160|40,112|101,509|
|Disposals||||(624)|(624)|
|At 30 September 2022||150,101|38,204|133,294|321,599|
|Net book value||||||
|At 30 September 2021||318,586|38,632|73,255|430,473|
|At 30September|2022|332,348|26,472|65,910|424,730|
##
|11
Investments|11
Investments|
|---|---|
|Investment|in subsididary|
|Movements|during the year|
|At I October||
|Additions||
|Disposals||
|Net losses|on investments|
##
|12|Debtors||||
|---|---|---|---|---|
||||2022|2021|
|Accrued|legacies||107,035|767,558|
|Amounts|owed by affiliates||425,551|628,030|
|Prep ay ments|||487,517|275,195|
|Amounts|owed by group undertakings||6,659|6,752|
|Trade debtors|||38,349|481,552|
||||1,065,111|2,159,087|
|13|Creditors: amounts|falling due within one year|||
||||2022|2021|
|Trade creditors|||461,761|198,165|
|Grant payable|||1,360,216|],217,281|
|Amounts|owed to affiliates»||532,887||
|Other creditors|||236,380|345,048|
||||2,591,244|1,760,494|
##
|14
Creditors:|amounts|falling|due after one year||||
|---|---|---|---|---|---|---|
||||||2022|2021|
|Grant payable|||||2,728,766|2,374,231|
|15
Guarantees|and other financial commitments||||||
|Operating|lease commitments
-land, building|||and equipment|||
||||||2022|2021|
|Total future minimum|lease payments||under non-cancellable||||
|opereating
leases for|each ofthe|following periods:|||||
|-not later than one year|||||468,000|468,000|
|-later than one year and not later than|||five years||2,113,800|2,067,000|
|-later than five years|||||386,100|900,900|
|Total|||||2,967,900|3,435,900|
##
##
|||2022|2021|
|---|---|---|---|
|Cash||6,659|6,752|
|Due to WCRF:||||
|Begriinning|balance|(6,750)|(6,843)|
|Net value|oftransactions|93|93|
|Amounts|owed by subsidiary|(6,657)|(6,750)|
|Total net|assets|||
##
|||||2022|||
|---|---|---|---|---|---|---|
|||WCRF||WCRF|WCRF||
|Description||International|AICR|NL|Hong Kong|Totals|
|Beginning|balance|212,399|192,036|180,653|42,942|628,030|
|Net value|oftransactions|170,210|(724,923)|(180,653)||(735,366)|
|Amounts|owed by affiliates|382,609|(532,887)||42,942|(107,336)|
|||||2021|||
|---|---|---|---|---|---|---|
|||WCRF||WCRF|WCRF||
|Description||International|AICR|NL|Hong Kong|Totals|
|Beginning|balance|143,290|627,503|157,212|42,942|970,947|
|Net value|oftransactions|69,109|(435,467)|23,441||(342,917)|
|Amounts|owed by affiliates|212,399|192,036|180,653|42,942|628,030|
##
|20
Anal|ysis ofNet|Assets be|tween Funds|||||
|---|---|---|---|---|---|---|---|
||||||2022|||
||||Tangible||Net|||
||||fixed||current|Long term||
||||assets|Investments|assets|liabilities|Totals|
|Unrestricted|funds|f.|424,730||8,523,202|(2,728,766)|6,219,166|
|Restricted|funds||||167,439||167,439|
|Total funds|||424,730||8,690,641|(2,728,766)|6,386,605|
||||||2021|||
||||Tangible||Net|||
||||fixed||current|Long term||
||||assets|Investments|assets|liabilities|Totals|
|Unrestricted|funds||493,471||8,335,609|(2,374,231)|6,454,849|
|Restricted|funds||||59,374||59,374|
|Total funds|||493,471||8,394,983|(2,374,231)|6,514,223|
##
##
##
||||Balance at|||Balance at|
|---|---|---|---|---|---|---|
||||I Oct 2021|Income|Expenditure|30Sep 2021|
|Restricted|funds||||||
|EC Co-Create Grant||f|51,874|96,577|(69,507)|78,944|
|Trusts/Foundations|||7,500|88,495|(7,500)|88,495|
||||59,374|185,072|(77,007)|167,439|